References analysis of the Wikipedia article "Buserelin" in the English version

books.google.com

Höffken K (6 December 2012). Peptides in Oncology I: LH-RH Agonists and Antagonists. Springer Science & Business Media. pp. 77–. ISBN 978-88-470-2186-0. Archived from the original on 11 February 2022. Retrieved 17 December 2017.

Index Nominum 2000: International Drug Directory. Taylor & Francis. 2000. pp. 149–. ISBN 978-3-88763-075-1. Archived from the original on 2017-03-12. Retrieved 2017-12-17.

Hemat RA (2 March 2003). Andropathy. Urotext. pp. 120–. ISBN 978-1-903737-08-8.

Becker KL (2001). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. pp. 973–. ISBN 978-0-7817-1750-2.

Corson SL, Derman RJ (15 December 1995). Fertility Control. CRC Press. pp. 249–250. ISBN 978-0-9697978-0-7.

Srivastava V (26 June 2017). Peptide-based Drug Discovery: Challenges and New Therapeutics. Royal Society of Chemistry. pp. 182–. ISBN 978-1-78262-732-6. Archived from the original on 28 October 2021. Retrieved 6 January 2018.

Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 514. ISBN 978-3-527-60749-5. Archived from the original on 2021-06-20. Retrieved 2020-09-19.

Önerci TM (17 August 2013). Nasal Physiology and Pathophysiology of Nasal Disorders. Springer Science & Business Media. pp. 208–. ISBN 978-3-642-37250-6. Archived from the original on 28 October 2021. Retrieved 6 January 2018.

Farkas E, Ryadnov M (31 August 2013). Amino Acids, Peptide and Proteins. Royal Society of Chemistry. pp. 227–. ISBN 978-1-84973-585-8. Archived from the original on 11 February 2022. Retrieved 17 December 2017.

Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE (12 September 2013). Abeloff's Clinical Oncology E-Book. Elsevier Health Sciences. pp. 446–. ISBN 978-1-4557-2881-7. Archived from the original on 11 February 2022. Retrieved 6 January 2018.

Bansal K (30 May 2013). Manual of Endometriosis. JP Medical Ltd. pp. 99–. ISBN 978-93-5090-404-6. Archived from the original on 11 February 2022. Retrieved 17 December 2017.

Gray AH, Wright J, Goodey V, Bruce L (June 2010). Injectable Drugs Guide. Pharmaceutical Press. pp. 98–. ISBN 978-0-85369-787-9. Archived from the original on 2022-02-11. Retrieved 2017-12-17.

Falcone T, Hurd WW (14 June 2017). Clinical Reproductive Medicine and Surgery: A Practical Guide. Springer. pp. 9–. ISBN 978-3-319-52210-4. Archived from the original on 28 October 2021. Retrieved 17 December 2017.

Annual Reports in Medicinal Chemistry. Academic Press. 8 September 1989. pp. 351–. ISBN 978-0-08-058368-6. Archived from the original on 11 February 2022. Retrieved 17 December 2017.

Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 192–. ISBN 978-1-4757-2085-3. Archived from the original on 12 March 2017. Retrieved 17 December 2017.

Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 57–. ISBN 978-94-011-4439-1. Archived from the original on 12 March 2017. Retrieved 17 December 2017.

Denis LJ, Griffiths K, Kaisary AV, Murphy GP (1 March 1999). Textbook of Prostate Cancer: Pathology, Diagnosis and Treatment: Pathology, Diagnosis and Treatment. CRC Press. pp. 308–. ISBN 978-1-85317-422-3. Archived from the original on 8 February 2021. Retrieved 25 December 2017.

doi.org

Brogden RN, Buckley MM, Ward A (March 1990). "Buserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile". Drugs. 39 (3): 399–437. doi:10.2165/00003495-199039030-00007. PMID 2109679. S2CID 195691965.

Wilczynski C, Emanuele MA (November 2014). "Treating a transgender patient: overview of the guidelines". Postgraduate Medicine. 126 (7): 121–128. doi:10.3810/pgm.2014.11.2840. PMID 25387220. S2CID 22639336.

Siristatidis CS, Gibreel A, Basios G, Maheshwari A, Bhattacharya S (November 2015). "Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction" (PDF). The Cochrane Database of Systematic Reviews. 2015 (11): CD006919. doi:10.1002/14651858.CD006919.pub4. hdl:2164/7687. PMC 10759000. PMID 26558801. Archived from the original on 2022-02-11. Retrieved 2019-09-24.

Rajfer J, Handelsman DJ, Crum A, Steiner B, Peterson M, Swerdloff RS (July 1986). "Comparison of the efficacy of subcutaneous and nasal spray buserelin treatment in suppression of testicular steroidogenesis in men with prostate cancer". Fertility and Sterility. 46 (1): 104–110. doi:10.1016/s0015-0282(16)49466-5. PMID 3087785.

Soloway MS (1988). "Efficacy of buserelin in advanced prostate cancer and comparison with historical controls". American Journal of Clinical Oncology. 11 (Suppl 1): S29–S32. doi:10.1097/00000421-198812001-00006. PMID 3133944. S2CID 10101250.

Faure N, Labrie F, Lemay A, Bélanger A, Gourdeau Y, Laroche B, Robert G (March 1982). "Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (LH-RH) agonist in adult men". Fertility and Sterility. 37 (3): 416–424. doi:10.1016/S0015-0282(16)46107-8. PMID 6800852.

Tolis G, Faure N, Koutsilieris M, Lemay A, Klioze S, Yakabow A, Fazekas AT (July 1983). "Suppression of testicular steroidogenesis by the GnRH agonistic analogue Buserelin (HOE-766) in patients with prostatic cancer: studies in relation to dose and route of administration". Journal of Steroid Biochemistry. 19 (1C): 995–998. doi:10.1016/0022-4731(83)90045-6. PMID 6411994.

Kuhl H, Kaplan HG, Taubert HD (March 1976). "[Effects of a new analogue of LH-RH, D-Ser(TBU)6- EA10-LH-RH, on gonadotropin liberation in males (author's transl)]". Deutsche Medizinische Wochenschrift. 101 (10): 361–364. doi:10.1055/s-0028-1104089. PMID 129323. S2CID 260086614.

Labrie F (August 2014). "GnRH agonists and the rapidly increasing use of combined androgen blockade in prostate cancer". Endocrine-Related Cancer. 21 (4): R301–R317. doi:10.1530/ERC-13-0165. PMID 24825748.

Klosterhalfen H, Jacobi GH (1988). "Long-term results of an LH-RH agonist monotherapy in patients with carcinoma of the prostate and reflections on the so-called total androgen blockade with pre-medicated cyproterone acetate". In Klosterhalfen H (ed.). Endocrine Management of Prostatic Cancer. pp. 127–137. doi:10.1515/9783110853674-014. ISBN 978-3-11-085367-4.

Matsumiya K, Kitamura M, Kishikawa H, Kondoh N, Fujiwara Y, Namiki M, Okuyama A (July 1998). "A prospective comparative trial of a gonadotropin-releasing hormone analogue with clomiphene citrate for the treatment of oligoasthenozoospermia". International Journal of Urology. 5 (4): 361–363. doi:10.1111/j.1442-2042.1998.tb00367.x. PMID 9712445. S2CID 24680327.

Iwamoto H, Yoshida A, Suzuki H, Tanaka M, Watanabe N, Nakamura T (September 2009). "A man with hypogonadotropic hypogonadism successfully treated with nasal administration of the low-dose gonadotropin-releasing hormone analog buserelin". Fertility and Sterility. 92 (3): 1169.e1–1169.e3. doi:10.1016/j.fertnstert.2009.05.090. PMID 19591988.

nih.gov

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

sanofi.ca

products.sanofi.ca

semanticscholar.org

api.semanticscholar.org

web.archive.org

"Suprefact - Buserelin Acetate (Product Monograph)" (PDF). Sanofi Aventis. August 10, 2015. Archived (PDF) from the original on April 23, 2018. Retrieved December 17, 2017.

"Suprefact Depot 2 months and Suprefact Depot 3 months (Product Monograph)" (PDF). Sanofi Aventis. August 10, 2015. Archived (PDF) from the original on June 19, 2018. Retrieved December 17, 2017.

"Buserelin". Archived from the original on 2018-03-12. Retrieved 2017-12-17.

"Buserelin - Pharm-Sintez - AdisInsight". Archived from the original on 2017-12-24. Retrieved 2017-12-17.

Index Nominum 2000: International Drug Directory. Taylor & Francis. 2000. pp. 149–. ISBN 978-3-88763-075-1. Archived from the original on 2017-03-12. Retrieved 2017-12-17.

Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 514. ISBN 978-3-527-60749-5. Archived from the original on 2021-06-20. Retrieved 2020-09-19.

"Buserelin". Archived from the original on 2018-01-06. Retrieved 2017-12-17.

"Drug Product Database Online Query". 25 April 2012. Archived from the original on 29 October 2020. Retrieved 17 December 2017.

"CinnaGen: CinnaFact". Archived from the original on 2018-01-06. Retrieved 2017-12-17.

"Suprefact (buserelin acetate)". medbroadcast.com. Archived from the original on 2021-09-21. Retrieved 2021-09-21.

Bansal K (30 May 2013). Manual of Endometriosis. JP Medical Ltd. pp. 99–. ISBN 978-93-5090-404-6. Archived from the original on 11 February 2022. Retrieved 17 December 2017.

Gray AH, Wright J, Goodey V, Bruce L (June 2010). Injectable Drugs Guide. Pharmaceutical Press. pp. 98–. ISBN 978-0-85369-787-9. Archived from the original on 2022-02-11. Retrieved 2017-12-17.

Annual Reports in Medicinal Chemistry. Academic Press. 8 September 1989. pp. 351–. ISBN 978-0-08-058368-6. Archived from the original on 11 February 2022. Retrieved 17 December 2017.

"Drugs@FDA: FDA Approved Drug Products". United States Food and Drug Administration. Archived from the original on 16 November 2016. Retrieved 17 December 2017.

Buserelin (English Wikipedia)

abdn.ac.uk

aura.abdn.ac.uk

books.google.com

canada.ca

health-products.canada.ca

cinnagen.com

doi.org

drugbank.ca

drugs.com

fda.gov

accessdata.fda.gov

handle.net

hdl.handle.net

medbroadcast.com